Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00974493
Other study ID # OVIVA
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 2010
Est. completion date February 28, 2017

Study information

Verified date June 2020
Source Oxford University Hospitals NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will compare the outcomes of treating bone and joint infections with 6 weeks of intravenous antibiotics with 6 weeks of oral antibiotic treatment. The trial is of antibiotic "strategy" rather than of individual antibiotics. The study will be open label, but the primary outcome will be proven failure of infection treatment, determined by pre-established objective criteria for treatment failure. The null hypothesis tested is that there will be no difference in treatment failure rates.


Description:

A long course of antibiotic therapy given by a "drip" (i.e. intravenous) is recommended treatment for many serious bacterial infections. It is costly and inconvenient for the patient to remain hospitalised for therapy, so outpatient antibiotic therapy (OPAT) programmes have been established in many countries to deliver intravenous antibiotics safely and conveniently. The majority of patients referred to OPAT programmes have bone and joint infections. However, there is no clear evidence that bone and joint infection really require long courses of intravenous antibiotics rather than oral antibiotics.

We will compare the outcome of treatment with intravenous versus oral antibiotic therapy for patients with bone and joint infection. The choice of antibiotic is complex, and antibiotics that are suitable oral choices are often not suitable intravenous choices and vice versa. Subjects will therefore be randomized to an oral or intravenous "strategy," rather than to individual antibiotics. Outcomes will be determined by pre-established objective criteria for treatment failure.

We have conducted a pilot study in one centre (Oxford), recruiting approximately 200 patients, and are now expanding to include multi-centre recruitment in the UK, aiming to recruit 1050 patients.


Recruitment information / eligibility

Status Completed
Enrollment 1054
Est. completion date February 28, 2017
Est. primary completion date March 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Is willing and able to give informed consent for participation in the study. Has a bone and joint infection one of the following categories;

1. Native osteomyelitis.

2. Native joint septic arthritis.

3. Diabetic foot infection with osteomyelitis.

4. Prosthetic joint associated infection.

5. Discitis/ spinal osteomyelitis/ epidural abscess

- Has had at least 48 hours, but not more than 7 days, of IV antibiotic therapy already given after definitive surgical management.

- Has a clinical diagnosis of bacterial infection (caused by any organism excepting mycobacteria).

- Is clinically stable in the opinion of the study clinicians, has no further interventions to treat acute infection required or planned.

Exclusion Criteria:

- Has Staph aureus bacteraemia.

- Has suspected bacterial endocarditis.

- Has suspected mediastinal infection.

- Has suspected central nervous system infection.

Study Design


Intervention

Drug:
Antibiotics
The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics. Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.

Locations

Country Name City State
United Kingdom Nuffield Orthopaedic Centre Oxford Oxfordshire
United Kingdom Oxford Radcliffe Hospitals Trust Oxford Oxfordshire

Sponsors (1)

Lead Sponsor Collaborator
Oxford University Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Frequency of Definite Failure of Infection Treatment. Number of participants with definite failure of infection treatment defined by microbiological, histological and clinical criteria and assessed by an independent blinded endpoint committee 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05519007 - Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone N/A
Active, not recruiting NCT04563325 - Oral-only Antibiotics for Bone and Joint Infections in Children Phase 4
Completed NCT05341908 - Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients
Recruiting NCT03550911 - Biological Collection From Samples From The Gut Microbiota In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine (CARBAMICROBIOTA)
Completed NCT04440631 - Gut Microbiome of Patients Undergoing Antibiotic Therapy for Orthopedic Device-related Infection
Recruiting NCT05753215 - Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection Phase 2
Recruiting NCT05137314 - Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA) Phase 1
Not yet recruiting NCT06293352 - Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection N/A
Recruiting NCT04304885 - Effect of Sonication on Periprosthetic Joint Infection Treatment Strategy.
Completed NCT03403608 - Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections N/A
Recruiting NCT03704766 - Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis N/A
Completed NCT03191292 - Bacterial Epidemiology and Empirical Antibiotherapy in Patients With Prosthetic Joint Infection N/A
Recruiting NCT06191601 - Interest in Probabilistic Antibiotic Therapy With Broad-spectrum Beta-lactams in Orthopedic Surgery
Completed NCT05804058 - Biofilm Composition as a Predictive Biomarker for Prosthetic Joint Infection
Enrolling by invitation NCT04723940 - Or v IV Antibiotics for Infection Phase 3
Completed NCT03426761 - Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections Phase 4
Enrolling by invitation NCT03713528 - Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI? Phase 4
Active, not recruiting NCT06402591 - Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen. Phase 3
Completed NCT04948281 - Joint Infection Following ACL Reconstruction
Completed NCT06267287 - Microbiological Structure of Pathogens of Periprosthetic Infection of Large Joints in the Post-Covid Period